First, elotuzumab binds primarily to SLAMF7 on MM cells and subsequently kills these cells through Fc-gamma receptor (FcγR) III (CD16)-dependent ADCC mediated by NK cells. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.